Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT03492801 Terminated - Clinical trials for Stage IV Non-Small Cell Lung Cancer AJCC v7

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Start date: December 11, 2017
Phase:
Study type: Observational

This pilot research trial studies the collection of blood samples in monitoring tumor specific mutations in patients with non-small cell lung cancer that has spread to other places in the body or cannot be removed by surgery. Collecting blood samples may help measure the changes in lung cancer, better learn methods to track cancer in the bloodstream, and improve cancer treatments.

NCT ID: NCT03488472 Terminated - Clinical trials for Small Cell Lung Cancer

Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain

RAD 1704
Start date: August 9, 2019
Phase: N/A
Study type: Interventional

This study is a prospective single arm trial designed to study the safety and effectiveness of a medical device, NovoTTF-200A, used with stereotactic radiosurgery (SRS) in subjects with brain metastases from small cell lung cancer (SCLC).

NCT ID: NCT03472560 Terminated - Clinical trials for Non-Small Cell Lung Cancer

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Start date: May 2, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.

NCT ID: NCT03455556 Terminated - Clinical trials for Stage IV Non-Small Cell Lung Cancer AJCC v7

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Start date: August 10, 2018
Phase: Phase 1
Study type: Interventional

This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other places in the body. Monoclonal antibodies, such as anetumab ravtansine and atezolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03447769 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Canopy-A
Start date: March 16, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of the study was to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages II -IIIA according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

NCT ID: NCT03445000 Terminated - Clinical trials for Non-small Cell Lung Cancer

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer

ALERT-lung
Start date: November 6, 2018
Phase: Phase 2
Study type: Interventional

A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.

NCT ID: NCT03436056 Terminated - Clinical trials for Metastatic Non-small-cell lunG Cancer

PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients

PRIMING
Start date: March 1, 2018
Phase: Phase 1
Study type: Interventional

This is a single centre non-randomised open label phase 1 trial of lung SBRT to part of a lung lesion in patients with advanced NSCLC in combination with pembrolizumab. This study will recruit up to 24 patients whose lung cancer has progressed beyond one line of palliative chemotherapy, and an EGFR or ALK inhibitor if an EGFR driver mutation or ALK gene rearrangement is present, respectively, and now requires further palliative systemic treatment.

NCT ID: NCT03425006 Terminated - Clinical trials for Non Small Cell Lung Cancer

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

Start date: June 18, 2018
Phase: Phase 2
Study type: Interventional

This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).

NCT ID: NCT03406715 Terminated - Lung Cancer Clinical Trials

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cell lung cancer. Immunotherapy is a cancer therapy that uses the body's immune system to fight cancer cells. This study can be divided into three different phases: initial Induction Immunotherapy, Maintenance Immunotherapy and Retreatment.

NCT ID: NCT03400748 Terminated - Lung Cancer Clinical Trials

ANET Electrosurgery Applicator Pilot Evaluation Study

Start date: April 23, 2018
Phase: N/A
Study type: Interventional

Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.